Laigo Bio Secures €11.5M Seed Round to Advance SureTAC™ Platform

Why It Matters

The funding validates investor confidence in membrane‑protein targeting, a frontier with significant therapeutic upside, and strengthens Europe’s emerging precision‑medicine pipeline.

Key Takeaways

• €11.5M seed round led by Kurma, Curie.
• SureTAC™ targets membrane proteins for degradation.
• Investors include Angelini Ventures, Eurazeo, Oncode Bridge.
• Funding accelerates preclinical development of novel therapies.
• Shows rising European venture interest in precision biotech.

Pulse Analysis

European biotech financing has entered a new phase, with seed rounds increasingly focused on platforms that address historically "undruggable" targets. Laigo Bio’s €11.5 million raise reflects a broader shift toward investing in technologies that can modulate membrane proteins, a class that comprises roughly 30 percent of the human proteome yet remains underexploited. By securing capital from both venture firms and strategic corporate investors, Laigo positions itself at the nexus of academic innovation and commercial translation, benefitting from a diversified capital base that can sustain long‑term R&D cycles.

The SureTAC™ platform leverages precision degradation mechanisms to selectively eliminate disease‑causing membrane proteins, differentiating itself from conventional inhibition approaches. This method promises higher specificity and reduced off‑target effects, addressing a critical gap in oncology where many driver proteins reside on the cell surface. As the industry seeks next‑generation modalities—such as PROTACs, molecular glues, and now membrane‑targeted degraders—Laigo’s technology could unlock therapeutic avenues for cancers that lack effective treatments, potentially reshaping the competitive landscape.

Strategic participation from Angelini Ventures, Eurazeo, and the Oncode Bridge Fund signals confidence not only in Laigo’s science but also in its commercial roadmap. These investors bring deep domain expertise, regulatory insight, and access to global networks, accelerating the path from bench to bedside. With the seed capital earmarked for preclinical validation and early IND‑enabling studies, Laigo is poised to generate pivotal data that could attract larger Series A funding or partnership deals. The momentum underscores Europe’s growing capability to nurture high‑impact biotech ventures and could inspire further capital inflows into precision‑medicine platforms.

Deal Summary

Dutch biotech Laigo Bio announced a €11.5 million seed financing to advance its proprietary SureTAC™ precision membrane protein degradation platform. The round was co‑led by Kurma Partners and Curie Capital, with participation from Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region and Cancer Research Horizons.